Amgen’s Mvasi Set For Blockbuster Status With 50% Share In US

Annualized Biosimilars Sales Tracking North Of $2bn On Bevacizumab Boom

 
• By Dean Rudge
Digital_Arrow
Amgen: Worldwide volume gains for bevacizumab will be offset somewhat by price declines • Source: Shutterstock

More from Biosimilars

More from Products